Benjamin J. Zeskind - 05 Feb 2025 Form 4 Insider Report for Immuneering Corp (IMRX)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Issuer symbol
IMRX
Transactions as of
05 Feb 2025
Net transactions value
$0
Form type
4
Filing time
07 Feb 2025, 16:10:23 UTC
Previous filing
19 Mar 2024
Next filing
20 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMRX Stock Option Award $0 +480,000 $0.000000 480,000 05 Feb 2025 Class A Common Stock 480,000 $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029.